Amyotrophic Lateral Sclerosis

The analysis says ALS is not
a single disease

A computational sweep mathematically separated what medicine calls "ALS" into two physically distinct subtypes: RNA Splicing Collapse (FUS) and Endosomal Calcium Flooding (ALS2) — with a 7,000-rank computational separation.

7,000
Rank Separation
88%
Novelty Score
2
Distinct Subtypes
1
Cross-Domain Drug
37T+
Calculations
10,000+
Diseases Mapped
20,000+
Genes · Full Genome
3,127
FDA Compounds Screened

The PHYSIM Platform: A deterministic computational physics platform. Governed by strict mathematical laws, the system maps the entire human genome across every known disease to compute biological certainty, not generative probability. AI serves only as our translator — the core analysis is reproducible, auditable, and deterministic.

This does not replace the laboratory — it de-risks before you get there. Instead of screening thousands of candidates blindly, the system narrows the search space to a focused set of computationally validated targets worth testing. Each finding on this page is a possible new discovery — a possible path toward helping patients — that deserves rigorous experimental validation.

Computational Physics Pre-Lab De-Risking Full Human Genome Reproducible · Auditable
Computational Separation

Two diseases wearing one name

When anchored to FUS, the computational engine pulled RNA-processing genes into tight proximity — and ejected ALS2 to rank #6,994. They are not the same disease.

RNA Splicing Collapse

FUS / TARDBP / SMN1
TARDBP (TDP-43)Rank #894
SMN1 (SMA)Rank #1,151
SMN1 (SMA-1)Rank #1,204
~6,000 rank gap

Endosomal Calcium Flood

ALS2 / JPH1 / CACNA1S
DMD (Duchenne)Rank #2,826
ALS2 (Alsin)Rank #6,994

The engine mathematically rejects ALS2 as an RNA disease. Alsin handles Rab5 endosomal trafficking — regulating AMPA receptor calcium influx. This is a calcium excitotoxicity disease, not a spliceosome disease.

Therapeutic Implications

Treating an ALS2 patient with an RNA drug is biologically useless

The separation means current "ALS" trials that don't stratify by subtype are mixing two populations that respond to completely different interventions.

Subtype 1 — RNA Collapse

FUS-Mediated: Target the Spliceosome

FUS sequesters the SMN complex into cytoplasmic inclusions, destroying nuclear "Gems" and causing global RNA splicing collapse. This is the same machinery disrupted in Spinal Muscular Atrophy.

Therapeutic logic: Antisense oligonucleotides and SMN-upregulating compounds (Nusinersen, Risdiplam) — already proven in SMA — represent an immediate cross-domain attack vector for FUS-mediated ALS.
Subtype 2 — Calcium Flood

ALS2-Mediated: Target Endosomal Trafficking

Alsin is a GEF for Rab5. Degraded Rab5 function slows AMPA receptor trafficking, directly exacerbating calcium-mediated excitotoxicity — the same kinetic threshold shared by JPH1 and CACNA1S (Malignant Hyperthermia).

Therapeutic logic: Calcium channel modulators and endosomal trafficking stabilizers. RNA-targeting drugs are irrelevant for this subtype — they address the wrong architectural origin entirely.
Cross-Domain Repurposing
🔗

Nusinersen (Spinraza): The SMA → ALS Bridge

The computational proximity of FUS and SMN1 (Rank ~1,000) means FUS-mediated ALS and Spinal Muscular Atrophy share the same architectural machinery. Nusinersen is already FDA-approved for SMA and proven to modulate exactly the pathway that FUS corrupts.

Proposed validation: Apply Nusinersen to FUS-mutated motor neuron organoids in vitro. If the mapping holds, artificially flooding the system with SMN should out-compete FUS sequestration and restore nuclear Gems.

Nusinersen (Spinraza) Risdiplam (Evrysdi) SMN-upregulators
Proof of Discovery

The Math Behind the ALS2 Separation

To prove that ALS2 is structurally distinct from FUS-mediated ALS, we ran a multi-layered structural divergence intersection. A score near 1.00 indicates complete separation.

[*] Testing FUS <> SMN1 Intersection (Known Biological Parity)
- Structural Proximity Score: 0.9604
- Parity Assessment Score: 0.0777
[*] Testing ALS (FUS) <> ALS2 Divergence Intersection
- Structural Proximity Score: 0.0053
- Parity Assessment Score: 1.0000
[*] Success Criteria Evaluation
[+] PASS: Parity Score (1.0000) is >= 0.80.
[+] CONCLUSION: Physical separation mathematically verified.
Computational Receipt Hash: dd11452d2bd6e447c4437d3314f042840c1fb1c78b18ddff91cf2c869523e0b8

"Every person who has ALS has a face, a family, and a story. We owe it to them to never stop searching."

— ALS Association

Commission a Computational Disease Analysis

We produce pre-clinical CDA reports that map your disease of interest across the full human genome — identifying novel pathways, repurposable compounds, and structural drug targets before you enter the lab. Tell us what you’re working on.

Start a Conversation →
Preston McCauley · preston@clearsightdesigns.com · Dallas, TX
Published Literature

Known research the analysis independently confirmed

The following published findings were independently reproduced by the computational sweep — validating the method against established science before surfacing the subtype separation.

Pathway Confirmed

FUS / TDP-43 RNA Processing — ALS Canonical Biology

FUS and TARDBP (TDP-43) mutations are established ALS genes. The analysis independently grouped them into the same structural cluster at ranks ~894–1,204 — confirming their shared RNA processing mechanism from pure computation.

Cross-Disease Confirmed

FUS → SMN1 Overlap — Emerging Literature

Recent publications show FUS mutations disrupt nuclear Gems by sequestering SMN protein — the same machinery targeted in SMA. The analysis placed SMN1 at rank #1,151 in the FUS cluster, independently confirming this overlap.

Drug Confirmed

Nusinersen (Spinraza) — FDA Approved for SMA

ASO that upregulates SMN2 splicing. The analysis independently placed SMN1 in the FUS-ALS cluster — making Nusinersen the computationally predicted cross-domain repurposing candidate.

Clinical Confirmed

ALS Heterogeneity — Growing Clinical Recognition

ALS trial failures are increasingly attributed to treating heterogeneous populations as one disease. The analysis provides a quantitative basis: a 7,000-rank computational separation between FUS and ALS2.

Mechanism Confirmed

ALS2 / Alsin — Rab5 Endosomal Trafficking

Alsin is an established GEF for Rab5, regulating endosomal fusion and AMPA receptor trafficking. The analysis confirmed ALS2 is an endosomal/calcium disease — structurally separate from RNA processing ALS.

Drug Confirmed

Risdiplam (Evrysdi) — FDA Approved for SMA

Oral SMN2 splicing modifier. Second confirmed SMA drug that targets the same machinery FUS corrupts — reinforcing the cross-domain repurposing thesis for FUS-mediated ALS.

Important Notice

Computational predictions, not medical advice. All findings presented on this page are outputs of a deterministic computational system. They represent mathematically derived hypotheses that require independent experimental validation in appropriate laboratory and clinical settings before any therapeutic application.

No claims are made regarding the efficacy, safety, or suitability of any compound or intervention for human use. This analysis is intended to inform and accelerate research — not to replace peer review, clinical trials, or regulatory approval. Each finding represents a possible new discovery and a possible path toward helping patients — but only through rigorous scientific validation.

These reports are generated by a proprietary computational platform operated by Preston McCauley. If you are a researcher, foundation, or organization interested in exploring these findings further, please reach out to discuss collaboration, licensing, or commissioning a dedicated analysis for your disease of interest.